Keywords: biopartners, responds, chmp, negative, opinion, alpheon, swiss
Biopartners responds to CHMP's negative opinion on Alpheon
Article | 10 July 2006
Swiss biopharmaceuticals firm Biopartners said that it was disappointed that Alpheon, its biosimilar version of interferon alpha, had received a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
